Labiotech.eu

hypermutation biofuels antimicrobial resistance cancer

News and Trends 9 May 2017

Hypermutation could be the Key to Biofuels – and Antibiotic Resistance

Instead of taking a spa vacation, stressed out bacteria start mutating their DNA fast. This nearly suicidal behavior can yield a lucky survivor in nature. For us, it could mean new strategies for biofuel production and fighting antibiotic resistance, researchers say. Researchers from the Centre of Microbial and Plant Genetics at KU Leuven, in Belgium, are shining […]

May 9, 2017 - 2 minutesmins - By Denise Neves Gameiro

In Depth 9 May 2017

Rise of the Superbugs: How is Biotech Fighting Antibiotic Resistance?

Fewer antibiotics are produced as development costs rise. We reached out to a few companies addressing the serious issue of antibiotic resistance. Antibiotic resistance is one of the greatest threats to our societies and health systems, and the number of antibiotic-resistant bacteria is growing at a disquieting rate. The estimated number of people killed by […]

May 9, 2017 - 8 minutesmins - By External Contributor

News and Trends 8 May 2017

The EU Approves New Treatment for a Rare Pediatric Cancer

Update (08/05/2017): The European Commission has granted marketing authorization to Apeiron Biologic’s APN311 in the rare pediatric cancer neuroblastoma. Originally published on 27/03/2017 Apeiron Biologics has announced that the EMA’s CHMP has recommended the approval of APN311 for immunotherapy of high-risk neuroblastoma. Apeiron Biologics is a Vienna-based biotech company developing immunological approaches to treat cancer. […]

May 8, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 8 May 2017

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

Teva and Active Biotech have failed Phase III with their Multiple Sclerosis drug laquinimod to treat the relapsing-remitting form of the disease. Teva and Active Biotech have faced another setback with their long-expected successor to Teva’s Copaxone, laquinimod, for the treatment of Multiple Sclerosis (MS). The drug failed to meet the primary endpoint, trying to improve the […]

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 8 May 2017

French Researchers Discover a Target to Prevent Zika Birth Defects

Researchers from the Institut Pasteur and the Inserm have identified a protein target that, when overexpressed, can block Zika infections. The recent Zika epidemics in the Pacific and South America has led the World Health Organization (WHO) to declare a state of global emergency. One of the biggest concerns at the moment is that the […]

May 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Immunocore GSK Immuno oncology collaboration

News and Trends 8 May 2017

Immunocore Boosts its Collaboration with GSK with new Lead Compound

Immunocore has singled out a new lead candidate in its immuno-oncology discovery program with GSK, triggering an undisclosed milestone payment to Immunocore. Based in Oxford, Immunocore is one of the hottest biotechs in the immuno-oncology space, which was able to raise one of the largest European private funding rounds ever (€300M) and is backed by […]

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

Seuss Consulting CRO Sponsor partnerhsip

News and Trends 8 May 2017

Top 5 Mistakes that Will Doom a CRO-Supplier Partnership Before it Starts

A healthy relationship between a trial sponsor and the CRO or supplier can be the key to success – here is a list of how to address the biggest challenges. By 2020, 72% of clinical trials are projected to be outsourced to contract research organizations (CROs), compared to just 23% in 2012. The main reason […]

May 8, 2017 - 7 minutesmins - By External Contributor

Interview 8 May 2017

Meet the co-developer of the first commercial mAb and gene therapy

Sander van Deventer is now a managing partner at Forbion after playing a critical role in the development of the first commercial monoclonal antibody, Remicade, and the first market-approved gene therapy, Glybera. I was curious to know what he did to achieve such an impressive track record. Sander van Deventer was trained as an internist […]

May 8, 2017 - 5 minutesmins - By Philip Hemme

More News! 6 May 2017

Color Patterns in the Clothes of the Future will be Made by Bacteria

Natsai Audrey Chieza is an artist and researcher exploring the integration of life into the manufacturing of the materials of the future. Natsai Audrey Chieza wants to break with the current paradigm of fashion design and textile production with the help of microbiology. Her research focuses on developing bacterial biopigments for textiles to replace the […]

May 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 May 2017

Forget Chemical Synthesis, Yeast can Now Synthesize Complex Antibiotics

A new study presents a novel synthetic biology approach for antibiotic synthesis in yeast that could tackle the huge challenge of antibiotic resistance. Scientists at Imperial College London have hacked their way into introducing complex biosynthesis pathways in the baker’s yeast Saccharomyces cerevisiae. In particular, they focused on the production of non-ribosomal peptides (Nrp), a group of […]

May 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 4 May 2017

Video Interview: This Biotech Wants to Take Over the NOTCH Space

Cellestia, based in Basel, is a biotech spin-off from EPFL, developing new compounds targeting the NOTCH pathway for the treatment of cancer. Its CEO, Michael Bauer, talked to Philip at our recent meetup in Basel and explained what sets Cellestia apart from other players in the field. Cellestia was founded in 2014, based on the […]

May 4, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 4 May 2017

Solid First-in-Human Results from Vaccine against Birth Defects

Hookipa has presented positive data from its first Phase I trial testing its vaccine technology against human cytomegalovirus (hCMV) infections. Hookipa, one of the top 10 biotechs we’re closely following this year, is developing a viral vaccine platform that has attracted big investments from both the private and the public sector. The company just announced […]

May 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Hypermutation could be the Key to Biofuels – and Antibiotic Resistance

Rise of the Superbugs: How is Biotech Fighting Antibiotic Resistance?

The EU Approves New Treatment for a Rare Pediatric Cancer

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

French Researchers Discover a Target to Prevent Zika Birth Defects

Immunocore Boosts its Collaboration with GSK with new Lead Compound

Top 5 Mistakes that Will Doom a CRO-Supplier Partnership Before it Starts

Meet the co-developer of the first commercial mAb and gene therapy

Color Patterns in the Clothes of the Future will be Made by Bacteria

Forget Chemical Synthesis, Yeast can Now Synthesize Complex Antibiotics

Video Interview: This Biotech Wants to Take Over the NOTCH Space

Solid First-in-Human Results from Vaccine against Birth Defects

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!